Thought Leadership

A searchable library for all Cerner Enviza thought leadership across
multiple channels. For clinical publications please click here.

Oncology & Rare Disease
Oncology Newsletter March 2022
The oncology race in biotech
The Oncology Race in Biotech
Many biotechs are looking for their first approval, including those with large clinical programs in the US and EU and ongoing Phase III trials.
Oncology Newsletter February 2022
Precision medicine the next generation and more
Precision Medicine: The Next Generation
For too long oncology patients have been treated with a one-size-fits-all treatment plan. The time has come for a more personalized approach.
Oncology Newsletter January 2022
The evolution of biomarker driven clinical development and more
Oncology Newsletter December 2021
The role of marketing in oncology and more
The burden of cancer caregiving across the globe
Data from the National Health & Wellness Survey suggests population aging and economic development influence the role of cancer caregivers and the degree of health, productivity, and financial impacts they report.
Oncology Newsletter │ November 2021
Technology tensions epidemiology projections and more
Evolution of biomarker trials across the tumor spectrum
Biomarker driven clinical trials have quickly built momentum in oncology. Explore and understand two decades of developmental trends across a variety of tumors.
White Paper
Evolving regulatory and reimbursement landscape
Cancer is a healthcare priority in all APAC markets. We provide an overview of China, Hong Kong, Japan, Singapore, South Korea and Taiwan.
CAR-T and the growth of cell therapy trials
While CAR-T therapies are the dominant approach globally with development focused in the US and China, other therapy approaches are steadily rising.
A Periodic Table of Biomarkers
Tumor-agnostic development strategies are gaining momentum as a way to treat solid and hematological tumors characterized by novel and existing biomarkers.
Navigating multiple myeloma
A more positive journey for patients with increased survival rates. View the some of the contributing factors over 2004 to 2014.
Better testing, better outcomes in Rare Cancer: NTRK fusions
The diverse nature of NTRK fusions present challenges for identification and diagnosis given their rarity and heterogenous patient populations.
The Breadth of PD(L)1 Development in 2021
Development of immuno-oncology drugs has risen dramatically. With 6 PD(L)1 agents now FDA approved, development now extends to multiple tumor types.
Better testing, better outcomes in Rare Cancer: BRCA mutation and PARP inhibitors
Could increased testing improve outcomes of more patients in rare cancer? And with HRR mutations occurring in multiple tumor types, are there more cancers these drugs can treat?
Pining hope on CDK4/6
While CDK4/6 inhibitors are at different stages of global adoption, they are indisputably the new standard of care bringing better outcomes to patients with HR+HER2- metastatic breast cancer.
The expanding and evolving NSCLC immuno-therapy universe
Use of PD(L)1 monoclonal antibodies (mABs) in NSCLC clinical trials has surged from 3% in 2012 to over 50% in 2017-19. View infographic for more details.